Torrent Pharma acquires four brands from Dr Reddy’s
The complete integration and transition of the brands are expected to be completed by June 2022
Torrent Pharma yesterday announced that it has entered into an agreement with Dr Reddy’s Laboratories to acquire four of its brands “Styptovit-E,” “Finast,” “Finast-T” and “Dynapress,” a statement from Torrent Pharma said.
Styptovit-E, a gynaecology product with an estimated market size of ~Rs 500 crores (AIOCD data set), will further strengthen Torrent’s presence in the therapy. The acquisition of “Finast”, “Finast-T” and “Dynapress,” which are used in the treatment of Benign Prostatic Hyperplasia (BPH), will aid in Torrent’s presence in the urology therapy, the statement added.
As per the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India. The complete integration and transition of the brands are expected to be completed by June 2022, concluded the statement.
- Advertisement -